1.Molecular characterisation and frequency of Ggamma Xmn I polymorphism in Chinese and Malay beta-thalassaemia patients in Malaysia.
Yean Ching Wong ; Elizabeth George ; Kim Lian Tan ; Sook Fan Yap ; Lee Lee Chan ; Jin Ai Mary Anne Tan
The Malaysian journal of pathology 2006;28(1):17-21
The molecular basis of variable phenotypes in P-thalassaemia patients with identical genotypes has been associated with co-inheritance of alpha-thalassaemia and persistence of HbF production in adult life. The Xmn I restriction site at -158 position of the Ggamma-gene is associated with increased expression of the Ggamma-globin gene and higher production of HbF This study aims to determine the frequency of the digammaferent genotypes of the Ggamma Xmn I polymorphism in P-thalassaemia patients in two ethnic groups in Malaysia. Molecular characterisation and frequency of the Ggamma Xmn I polymorphism were studied in fifty-eight Chinese and forty-nine beta-thalassaemia Malay patients by Xmn I digestion after DNA amplification of a 650 bp sequence. The in-house developed technique did not require further purification or concentration of amplified DNA before restriction enzyme digestion. The cheaper Seakem LE agarose was used instead of Nusieve agarose and distinct well separated bands were observed. Genotyping showed that the most frequent genotype observed in the Malaysian Chinese was homozygosity for the absence of the Xmn I site (-/-) (89.7%). In the Malays, heterozygosity of the Xmn I site (+/-) was most common (63.3%). Homozygosity for the Xmn I site (+/+) was absent in the Chinese, but was confirmed in 8.2% of the Malays. The ratio of the (+) allele (presence of the Xmn I site) to the (-) allele (absence of the Xmn I site)) was higher in the Malays (0.66) compared to the Chinese (0.05). The (+/-) and (+/+) genotypes are more commonly observed in the Malays than the Chinese in Malaysia.
Chinese People
;
Thalassemia
;
With frequency
;
Malaysia
;
seconds
2.Knowledge and Acceptance of COVID-19 (SARS CoV2) Vaccination among Foundation students in a College in Kedah, Malaysia
Sook-Ching Chan ; Muhamad Shahril Aiman Azrizal ; Ahmad Haziq Danial Ahmad Kamal Ariffin ; Muhammad Ilham Fahmi Mohd Zukri ; Muhammad Arees Mohamed Anwar ; Abu Ubaidah Amir Muhamad Sharman ; Muhammad Afif Shah Mohammad Aziz Shah
Malaysian Journal of Medicine and Health Sciences 2022;18(No.5):79-85
Introduction: To combat the COVID-19 pandemic, Malaysia started vaccination of front-liners and adults in the community. The latter group might have insufficient knowledge to accept COVID-19 vaccination, therefore this research
was to assess the knowledge and acceptance of COVID-19 vaccination among youths, specifically students in a
Malaysian college. Methods: A cross-sectional study was conducted among 481 foundation students in Kolej MARA
Kulim (KMKU). The minimum sample size, using Epi Info was 214. Students answered an online questionnaire using
google form which included demographic data (age, gender) and ten questions on knowledge and acceptance of
COVID-19 vaccination. For knowledge questions, students answered “yes”, “no” or “don’t know”, correct answer
scoring 1. For acceptance questions, a 5-point Likert scale was used ranging from “strongly disagree” to “strongly
agree”. EXCEL and SPSS version 23 were used for analysis with Chi-square test done to test association (significant for
p-value <0.05). Results: The response rate was 65.1% with 313 students, (45.4% males, and 54.6% females) aged
18-19 years. The majority (83.7%) had satisfactory to excellent knowledge scores (mean = 6.66 (SD=2.299, 95%
CI 6.40-6.91), median = 7 (± IQR =3), while 16.3% obtained poor scores (≤ 4). The majority (90%) accepted vaccination. Higher knowledge scores were associated with higher acceptance rates in both genders (p-value= 0.000).
Significantly more females (90.6%) than males (80.3%) had positive attitude towards vaccination (p-value = 0.009).
Conclusions: The majority of the foundation students in KMKU were knowledgeable on COVID-19 vaccination and
willing to receive the vaccination against the novel coronavirus.